Pamisel, Clinical Progress in Allogeneic Stem Cell Therapy for Chronic Kidney Disease

[Asia Economy Reporter Hyungsoo Park] Pharmicell is accelerating the recruitment of clinical trial participants for the chronic kidney disease treatment ‘Cellgram-CKD’.

Pharmicell announced on the 16th that no serious adverse reactions were reported in the early safety evaluation during the Phase 1 clinical trial of Cellgram-CKD, an allogeneic stem cell therapy.

In the early safety evaluation, Cellgram-CKD was intravenously administered a total of three times at two-week intervals to three patients. Observations up to one month after administration showed no adverse reactions of Grade 3 or higher related to the investigational drug according to the NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) standards.

Professor Hyo-Sang Kim of the Department of Nephrology at Seoul Asan Medical Center stated, "By administering mesenchymal stem cells, structural and functional recovery of the kidney can be expected through neovascularization and reduction of renal fibrosis," adding, "Since no significant adverse reactions were observed after Cellgram-CKD administration, we will accelerate the clinical trial process."

Pharmicell received approval for the Phase 1 clinical trial of Cellgram-CKD in July last year. The trial is being conducted at Seoul Asan Medical Center with 10 patients diagnosed with chronic kidney disease to evaluate safety and potential therapeutic effects. Cellgram-CKD’s main component is allogeneic bone marrow-derived mesenchymal stem cells, which are selected and expanded from healthy donors’ bone marrow to ensure consistent therapeutic efficacy across multiple patients.

The Phase 1 clinical trial of Cellgram-CKD is being conducted as part of the Advanced Medical Technology Development project supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute.

This content was produced with the assistance of AI translation services.